Kilitch Drugs (India) Limited (NSE:KILITCH)

Market Cap	5.77B +11.6%
Revenue (ttm)	2.07B +13.8%
Net Income	264.30M +35.5%
EPS	15.94 +31.4%
Shares Out	n/a
PE Ratio	21.83
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,268
Average Volume	25,100
Open	334.50
Previous Close	329.15
Day's Range	327.95 - 335.00
52-Week Range	299.95 - 500.00
Beta	-0.23
RSI	45.55
Earnings Date	Feb 11, 2026

About Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 187
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KILITCH

Financial Performance

In fiscal year 2025, Kilitch Drugs (India)'s revenue was 1.98 billion, an increase of 28.47% compared to the previous year's 1.54 billion. Earnings were 267.01 million, an increase of 82.86%.